Department of Intensive Care Medicine, Academic Medical Center, University of Amsterdam, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands.
Trials. 2011 Dec 23;12:266. doi: 10.1186/1745-6215-12-266.
Fresh frozen plasma (FFP) is an effective therapy to correct for a deficiency of multiple coagulation factors during bleeding. In past years, use of FFP has increased, in particular in patients on the Intensive Care Unit (ICU), and has expanded to include prophylactic use in patients with a coagulopathy prior to undergoing an invasive procedure. Retrospective studies suggest that prophylactic use of FFP does not prevent bleeding, but carries the risk of transfusion-related morbidity. However, up to 50% of FFP is administered to non-bleeding ICU patients. With the aim to investigate whether prophylactic FFP transfusions to critically ill patients can be safely omitted, a multi-center randomized clinical trial is conducted in ICU patients with a coagulopathy undergoing an invasive procedure.
A non-inferiority, prospective, multicenter randomized open-label, blinded end point evaluation (PROBE) trial. In the intervention group, a prophylactic transfusion of FFP prior to an invasive procedure is omitted compared to transfusion of a fixed dose of 12 ml/kg in the control group. Primary outcome measure is relevant bleeding. Secondary outcome measures are minor bleeding, correction of International Normalized Ratio, onset of acute lung injury, length of ventilation days and length of Intensive Care Unit stay.
The Transfusion of Fresh Frozen Plasma in non-bleeding ICU patients (TOPIC) trial is the first multi-center randomized controlled trial powered to investigate whether it is safe to withhold FFP transfusion to coagulopathic critically ill patients undergoing an invasive procedure.
Trial registration: Dutch Trial Register NTR2262 and ClinicalTrials.gov: NCT01143909.
新鲜冷冻血浆(FFP)是一种有效的治疗方法,可纠正出血期间多种凝血因子的缺乏。在过去几年中,FFP 的使用有所增加,尤其是在重症监护病房(ICU)的患者中,并已扩展到包括在接受侵入性操作前存在凝血功能障碍的患者中预防性使用。回顾性研究表明,预防性使用 FFP 并不能预防出血,但存在与输血相关的发病率的风险。然而,高达 50%的 FFP 被用于非出血性 ICU 患者。为了研究在危重病患者中预防性输注 FFP 是否可以安全地省略,一项多中心随机临床试验正在接受侵入性操作的凝血功能障碍的 ICU 患者中进行。
一项非劣效性、前瞻性、多中心随机开放标签、盲终点评估(PROBE)试验。在干预组中,与对照组中输注固定剂量的 12 ml/kg 相比,省略了侵入性操作前预防性输注 FFP。主要结局测量是相关出血。次要结局测量是轻微出血、国际标准化比值的校正、急性肺损伤的发生、通气天数和 ICU 住院时间。
在非出血性 ICU 患者中输注新鲜冷冻血浆(TOPIC)试验是第一项多中心随机对照试验,旨在研究在接受侵入性操作的凝血功能障碍的危重病患者中是否可以安全地省略 FFP 输注。
荷兰试验注册 NTR2262 和 ClinicalTrials.gov:NCT01143909。